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In recent years, the bidirectional relationship between the nervous and immune sys-
tem has become increasingly clear, and its role in both homeostasis and inflammation 
has been well documented over the years. Since the introduction of the cholinergic 
anti-inflammatory pathway, there has been an increased interest in parasympathetic reg-
ulation of both innate and adaptive immune responses, including T helper 2 responses. 
Increasing evidence has been emerging suggesting a role for the parasympathetic 
nervous system in the pathophysiology of allergic diseases, including allergic rhinitis, 
asthma, food allergy, and atopic dermatitis. In this review, we will highlight the role of 
cholinergic modulation by both nicotinic and muscarinic receptors in several key aspects 
of the allergic inflammatory response, including barrier function, innate and adaptive 
immune responses, and effector cells responses. A better understanding of these cho-
linergic processes mediating key aspects of type 2 immune disorders might lead to novel 
therapeutic approaches to treat allergic diseases.
Keywords: parasympathetic nervous system, allergic inflammation, type 2 immunity, cholinergic anti-inflammatory 
pathway, neuroimmune interactions, vagus nerve
iNTRODUCTiON
Evidence is accumulating that extrinsic nerves intensely and bidirectionally communicate with 
the immune system. Indeed, in 2000, Tracey and coworkers introduced the novel concept of the 
“inflammatory reflex,” where afferent vagal fibers sense peripheral inflammation and inform 
the brain on the inflammatory status to subsequently trigger vagal efferent fibers to dampen the 
inflammatory response (1). The cross talk between the vagus nerve and the immune system has 
been largely attributed to dampening of the innate immune system, in particular by reduction of 
cytokine release by splenic macrophages (2, 3). Since then, vagus nerve stimulation (VNS) has 
been evaluated in several inflammatory models characterized by not only activation of the innate 
immune system but also the adaptive immune system, but also the adaptive Immune system, par-
ticularly Th1 or Th17 immune responses (4, 5). Clinical observations, however, indirectly suggest 
that cholinergic immune modulation may also be of interest in atopic disorders characterized by T 
helper 2 (Th2) responses. Nicotine, a major constituent of cigarette smoke and a ligand for nicotinic 
acetylcholine receptors (nAChRs), has been implicated in anti-inflammatory effects seen in cor-
relation with smoking. However, a rather complex relationship exists between smoking and the 
incidence of allergic diseases; on the one hand, cigarette smoke has been reported to cause impaired 
lung function, consequently aggravating asthma symptoms, and additionally also increase the risk 
to develop atopy, asthma, and food allergy (6–10). Oppositely, other reports indicated an inverse 
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correlation between smoking and allergic disease incidence. 
Epidemiological studies demonstrated that the occurrence of 
asthma could be higher in former smokers, compared with 
active smokers (11–13). In addition, other studies have observed 
a negative association between smoking and the development of 
allergic sensitization (14, 15). In accordance with this, in a recent 
study Tilp et al. demonstrated that cigarette smoke reduces the 
allergen-induced Th2 response in the lung and the development 
of airway hyperreactivity (AHR) in a severe model of asthma in 
mice (16). Similarly, the adverse effects of excessive psychologi-
cal stress on the incidence and severity of allergic disorders have 
been acknowledged for long time (17). Interestingly, anxiety and 
depression have been associated with a decrease in vagal tone, 
leading to the exploration of VNS as a treatment for depression 
(18–21). The possibility exists that the decrease in vagal tone 
leads to a reduction in cholinergic modulation promoting allergic 
inflammation. This theory is supported by a study demonstrating 
that impaired parasympathetic function increased susceptibility 
to inflammatory bowel disease in a mouse model of depression 
(22). Furthermore, acetylcholinesterase (AChE) inhibitors, 
which have been successfully used in animal models to activate 
the cholinergic anti-inflammatory pathway, are widely used in 
the clinic to treat Alzheimer’s disease (AD) (23–26). Curiously, 
AD patients treated with the AChE inhibitor, donepezil, showed 
increased serum levels of interleukin (IL)-4 and MCP-1, sug-
gesting a possible shift toward a Th2 immune response (27). 
In addition, the effect of organophosphate compounds (OPCs), 
which are used as pesticides and are known AChE inhibitors, 
has been tested in allergic animal models. However, contrasting 
results have been obtained, whereas some studies mention an 
aggravation of allergic immune responses, other studies report 
an overall immunosuppressive effect (28–31). This discrepancy 
might be attributed to the timing of exposure, as a recent study 
showed that exposure to OPCs before allergen sensitization 
leads to worsening of allergic inflammation, while coinstan-
taneous exposure leads to suppression (31). Over the years, 
the importance of cholinergic modulation in inflammatory 
conditions has become increasingly clear. Although the role of 
parasympathetic regulation in allergic disorders has not been 
investigated extensively, more evidence is emerging supporting 
a role for cholinergic modulation in Th2-mediated disorders. 
Therefore, in this review, we aim to provide an overview of recent 
discoveries and its implications in relation to this research area.
PATHOPHYSiOLOGY OF ALLeRGiC 
iNFLAMMATiON
At mucosal surfaces, the epithelium is crucial for maintaining a 
physical barrier and protect against environmental insults and 
allergens. In addition, it forms a functional barrier allowing 
communication between the internal and external environ-
ment. A whole array of different immune cells exists within 
the mucosal barrier, constantly surveying the environment and 
ready to provide innate and adaptive immunity. Many allergic 
diseases typically coincide with disorders of the epithelial bar-
rier, which is associated with loss of epithelial differentiation, 
reduced junctional integrity, and impaired innate defense. For 
a long time, barrier dysfunction was seen as a consequence of 
the aberrant immunological response toward allergens. Recent 
evidence, however, suggests that barrier dysfunction also may 
act as an important initiator and player in the pathophysiol-
ogy of allergic inflammation. The barrier can be disrupted by 
a number of factors arising from the external environment, 
such as proteases, toxins, or injury, but also endogenous factors 
such as hormones, diet, and circadian clock could contribute. 
Disruption of the barrier might result in increased antigen uptake 
and can drive predisposition to allergic sensitization (32, 33). 
On exposure, allergens are sensed by epithelial cells, which in 
turn lead to the rapid release of epithelial cytokines, IL-25, IL-33, 
and thymic stromal lymphopoietin (TSLP) (34). These epithelial 
cytokines are able to induce expression and release of type 2 
cytokines by type 2 innate lymphoid cells (ILC2s). This creates an 
environment that promotes the generation of allergen-specific 
Th2 cells, a process that is mainly driven by antigen presenting 
cells, primarily dendritic cells (DCs). DCs are responsible for 
taking up, processing and presenting allergens to naïve T cells. 
Th2 cells then play a central role, orchestrating different events of 
the inflammatory allergic response, mainly through the release 
of type 2 cytokines such as IL-4, IL-5, IL-9, and IL-13. These 
events include the attraction of effector cells such as eosinophils, 
mast cells, and basophils to the site of inflammation. In addition, 
B-cell class switching will be promoted under the influence of 
IL-4 and IL-13, leading to an increased production of allergen-
specific immunoglobulin E (IgE). Upon allergen reexposure, IgE 
is able to bind FcεRIα on the surface of mast cells and basophils 
leading to their activation. This cascade of events can occur at 
different sites throughout the body and represent the underlying 
mechanism of disorders such as allergic rhinitis, asthma, food 
allergy, and atopic dermatitis (Figure 1) (35, 36).
THe CHOLiNeRGiC NeRvOUS SYSTeM  
iN GUT, LUNG AND SKiN
Barrier surfaces such as the gastrointestinal (GI) tract, res-
piratory tract, and skin are densely populated by neurons 
and immune cells that constantly sense and respond to 
environmental challenges, including allergens. The peripheral 
nervous system (PNS) consists of the somatic nervous system 
and the autonomic nervous system. The latter can be further 
subdivided into the parasympathetic, sympathetic, and enteric 
nervous system (ENS). The different neurons of the PNS have 
been found to communicate with the immune system through 
the release of neuromediators from their nerve terminals. The 
parasympathetic nervous system primarily uses the neurotrans-
mitter acetylcholine (ACh). As in this review, the focus will be 
on cholinergic modulation of the immune response, we will first 
describe the parasympathetic innervation and cholinergic input 
at the different epithelial barriers typically involved in allergic 
conditions.
The gut is densely innervated by the autonomic nervous sys-
tem, consisting of the extrinsic innervation and the ENS, located 
within the intestine. The vagus nerve, providing a bidirectional 
FiGURe 1 | Cholinergic modulation of type 2-mediated inflammation. (A) Allergen exposure evokes the rapid release of epithelial cytokines (IL-25, IL-33, and TSLP), 
which in turn drives the production of type 2 cytokines by ILC2s. This creates an environment that further facilitates DCs to promote the differentiation of naive 
T cells toward Th2 cells. These Th2 cells will then orchestrate different events of the inflammatory allergic response, through the release of type 2 cytokines (IL-4, 
IL-5, IL-9, and IL-13), including the attraction of effector cells (eosinophils, mast cells, and basophils) to the site of inflammation. In addition, B-cell class switching is 
promoted, leading to the production of allergen-specific IgE. Binding of antigen to IgE bound on mast cells and basophils leads to IgE cross-linking and subsequent 
activation. (B) ACh is able to modulate several key processes of the allergic inflammatory response via muscarinic and nicotinic receptors. ACh, acetylcholine; TSLP, 
thymic stromal lymphopoietin; DC, dendritic cell; ILC2, type 2 innate lymphoid cell; Th, T helper cell; IgE, immunoglobulin E; mAChR, muscarinic acetylcholine 
receptor; nAChR, nicotinic acetylcholine receptor; IL, interleukin; Th2, T helper 2.
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connection between the brain and the gut, represents the main 
extrinsic parasympathetic nerve in the GI tract, where it mainly 
controls secretion, vascularization, and gastrointestinal motility. 
Preganglionic efferent vagal nerve fibers extensively innervate 
the GI tract, displaying the highest density in the stomach and 
further decreasing in the small bowel and colon, and establish-
ing connections with postganglionic neurons primarily located 
in the myenteric plexus (37, 38). However, as vagal efferents 
only synapse with cholinergic enteric neurons in the myenteric 
plexus, it is likely that they affect mucosal immune responses 
indirectly through activation of cholinergic ENS neurons releas-
ing ACh (39).
In the lung, the parasympathetic nervous system plays a 
prominent role in the control of airway smooth muscle tone. ACh 
released from postganglionic neurons induces bronchoconstric-
tion, mucus secretion, and bronchial vasodilation, primarily 
mediated via binding on muscarinic receptor M3 (40, 41). For 
this reason, anticholinergic and muscarinic antagonists have 
been used to treat bronchoconstriction in asthma. The prominent 
role of the parasympathetic nervous system in the pathophysiol-
ogy of asthma makes it challenging to investigate its role in the 
modulation of the immune response.
In contrast to the GI and the respiratory tract, the skin is 
devoid of parasympathetic innervation (41). This might question 
a role for cholinergic modulation of immune responses in the 
skin and in diseases, such as atopic dermatitis. However, the skin 
contains other sources of ACh, in particular keratinocytes (42), 
but in fact almost every cell, including epithelial, endothelial, 
and immune cells can produce ACh. Hence, this so-called “non-
neural cholinergic system” might not only be of relevance in the 
skin but also in the gut and lung (43).
CHOLiNeRGiC MODULATiON OF 
BARRieR FUNCTiON
Improving epithelial barrier function could result into a 
decreased access of allergens, limiting the subsequent type 2 
inflammatory response. Although there is no direct evidence for 
cholinergic modulation of epithelial barrier function in allergic 
disorders, some studies do suggest a role for ACh in modulating 
barrier integrity. ACh was shown to play a role in the regulation 
of epithelial tightness in pig colon cultures. Incubation with 
carbachol resulted into an increased transepithelial electrical 
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resistance, an effect that was inhibited by atropine, suggesting 
involvement of muscarinic acetylcholine receptors (mAChRs) 
(44). In addition, muscarinic agonists where shown to stimulate 
epithelial cell proliferation, increasing mucosal thickness in 
the intestine. Moreover, in several inflammatory conditions, 
cholinergic modulation was seen to protect barrier integrity due 
to improved tight junction protein expression (45–48). However, 
this effect is probably indirectly regulated by the downregula-
tion of pro-inflammatory cytokines. Although the cholinergic 
modulation of barrier function in type 2-mediated diseases has 
been relatively unexplored so far, it might hold yet undiscovered 
potential toward therapeutic interventions.
The epithelium should not be considered as merely a physi-
cal barrier controlling the uptake and transport of antigens; in 
addition, it should be seen as an active contributor to the 
mucosal environment helping to shape local immune reactions. 
Epithelial derived cytokines IL-25, IL-33, and TSLP have been 
shown to play a role in the initiation of type 2 allergic responses. 
Preventing the expression and release of epithelial cytokines 
might be sufficient to prevent the subsequent Th2 immune 
response. Evidence that cholinergic modulation might influence 
this process was recently provided by a study showing inhibition 
of TSLP expression both in vitro and in vivo by nicotine. This 
effect was abolished by pretreatment with α7 nAChR antago-
nists, showing the involvement of α7 nAChR (49).
Experimental and clinical data have supported a role for 
type 2 cytokines in the regulation of intestinal barrier function. 
IL-4 and IL-13 have been shown to increase intestinal perme-
ability, an effect that is mediated via phosphoinositide 3-kinases 
(50–53). In addition, allergic effector cells such as mast cells and 
eosinophils release powerful inflammatory mediators, such as 
proteases and cytokines, further contributing to barrier dys-
function (52, 54–56). Cholinergic modulation of immune cells 
involved in the allergic inflammatory response might therefore, 
in addition to direct effects that will be described in detail below, 
also contribute to effects on barrier function.
CHOLiNeRGiC MODULATiON OF THe 
TYPe 2 iNNATe iMMUNe ReSPONSe
The innate immune system plays an important role in the ini-
tiation of subsequent adaptive immune response. Key players of 
type 2 innate immunity include recently described ILC2s that 
produce cytokines promoting Th2 differentiation by DCs, which 
are considered as a crucial link between innate and adaptive 
immunity.
Interestingly, a recent study showed that ILC2 might be modu-
lated by cholinergic signals. Indeed, α7 nAChR expression has 
been shown on ILC2, whereas in vitro incubation of pulmonary 
ILC2s with GTS-21, a specific α7 nAChR agonist suppressed pro-
duction of IL-5 and IL-13 cytokines, proliferation, and GATA3 
expression. In addition, GTS-21 treatment ameliorated ILC2 
induced AHR. Similar observations were made in a humanized 
ILC2 AHR mice model (57). These findings suggest that cholin-
ergic modulation of ILC2s via the α7 nAChR is a potential target 
for therapeutic intervention in type 2-mediated disorders.
In contrast to the well described anti-inflammatory effect 
of ACh on macrophages (39, 58–60), the effect of cholinergic 
modulation on DCs has been far less studied. Aicher et al. demon-
strated the expression of α7 nAChR on human monocyte-derived 
DCs, which was upregulated in response to its ligand nicotine (61). 
In addition, murine bone marrow-derived DCs expressed 
mRNAs encoding the five mAChR subtypes (M1–M5) and the 
α2, α5, α6, α7, α10, and β2 nAChR subunits (62). Earlier reports 
suggested an anti-inflammatory effect of nicotine reducing 
endocytosis, phagocytosis, the production of pro-inflammatory 
cytokines IL-12, IL-1β, and TNF-α and the ability to induce a 
Th1 response (63). By contrast, other reports stated that nicotine 
activated DC function, enhancing endocytosis, stimulation of 
T cell proliferation, and the production of IL-12 (61, 64). These 
opposing results might be due to differences in maturation and 
activation state. More recently, Gori et al. demonstrated a role 
for ACh in polarizing DCs toward a Th2-promoting phenotype. 
Treatment of DC with ACh stimulated the expression of the Th2-
promoter OX40L, the production of Th2-chemokines CCL22 
and CCL17, and the synthesis of IL-4, IL-5, and IL-13 by T cells 
(65). This study was in line with earlier findings by Liu et  al. 
showing that the muscarinic receptor agonist, methacholine, 
increased OX40L in DCs (66). These data suggest an involvement 
of mAChRs in the Th2 polarizing effect of ACh on DCs.
CHOLiNeRGiC MODULATiON OF THe 
TYPe 2 ADAPTive iMMUNe ReSPONSe
Given that DCs form a bridge between the innate and adaptive 
immune responses, cholinergic modulation of these cells as 
described earlier will definitely influence consequent adaptive 
immune responses. However, both T and B lymphocytes are 
also directly modulated by ACh, as several nAChR and mAChRs 
subtypes have been reported in both cell types (67–70).
As for other immune cells, also T cells show a high degree 
of plasticity with respect to their cholinergic receptor network. 
Depending on their activation state, differentiation state or even 
environmental cues, T cells will express a different repertoire 
of ACh receptors (71). So far, especially α7 nAChR has been 
investigated in the context of the cholinergic anti-inflammatory 
pathway (1). Although the expression of the α7 nAChR subunit 
has been demonstrated in activated CD4 T cells, surprisingly 
Th1, Th2, or Th17  cells do not express detectable levels of 
this receptor (71). In addition, Although vagotomy has been 
shown to increase T cell proliferation and production of pro-
inflammatory cytokines, this effect is not attenuated by selec-
tive α7 nAChR agonists, suggesting the involvement of other 
subunits such as α4, β2, and α5 (69, 72, 73). Other studies, 
however, do highlight the importance of the α7 nAChR in the 
anti-inflammatory effect of nicotine. Interestingly, a study by 
Galitovskiy et al. showed that α7 nAChR mRNA expression in 
colonic CD4 T cells was highly dependent on the inflammatory 
milieu. IL-4 was shown to upregulate α7 nAChR gene expres-
sion, whereas it was reduced by IL-12, possibly explaining the 
dualistic effect of nicotine in ulcerative colitis (Th2) versus 
Crohn’s disease (Th1/Th17) (74). This finding is especially 
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of interest in allergic disorders, which are characterized by a 
strong type 2 inflammatory environment. In addition, a more 
recent study proposed α7 nAChR as a critical regulator for the 
immunosuppressive function of Tregs, mainly due to upregula-
tion of immunoregulatory molecules CTLA-4 and FoxP3, and 
decreasing IL-2 levels (75). Considering the crucial role of Tregs 
in immune homeostasis and their capacity to suppress Th2 
responses to allergens and other type 2 effector cells, novel ways 
to promote Treg cell stability and function, are being explored 
extensively in the treatment for allergic diseases. Whereas there 
has been an increasing appreciation for nicotinic receptors in 
the modulation of inflammation and homeostasis, muscarinic 
receptors have received much less attention so far. Of note, sev-
eral studies have highlighted the importance of the M3 receptor 
in the generation of type 2 immune responses. Stimulation of 
mAChRs on naïve CD4 T cells promotes Th2 and Th17 lineages, 
while blockade of mAChR will lead to Th1 differentiation (71). 
Moreover, two recent studies demonstrated the importance 
of M3 receptor activity in the generation of Th2 responses in 
an enteric nematode infection model and an allergic airway 
inflammation model (76, 77). These studies suggest that the M3 
receptor opposes the effect of α7 nAChR receptor activation 
(77). It should be emphasized though that the range of doses 
that activates each receptor is some log units apart, questioning 
if this interplay is indeed of physiological relevance. So far, most 
findings concerning cholinergic modulation of T cells are based 
on in vitro studies, hardly representing the complex nature of 
the inflammatory environment. Therefore, to better understand 
the functional consequences of cholinergic activation on T cells 
in vivo, further studies in experimental models are needed.
As mentioned earlier, functional expression of nAChR 
subunits and mAChRs subtypes has also been demonstrated 
in B cells (67–70). Information on the functional implications 
of cholinergic receptor activation is, however, rather limited. 
Nicotine affects the survival of B lymphocyte precursors during 
differentiation, an effect that was dependent on both α7 and β2 
subunits (78). In addition, effects on antibody responses have 
been reported. A study by Skok et al. described a role α4β2 and 
α7 nAChRs in the formation of the pre-immune status and the 
regulation of antibody response, possibly by affecting CD40 
expression and/or signaling. Mice lacking α4, β2, or α7 nAChR 
subunits exhibited lower levels of IgG antibodies (79, 80). By 
contrast, Fuji et al. reported higher levels of IgG1 antibodies in 
α7 nAChR knockout mice (81). The reason for this discrepancy 
is still unclear. However, both studies reported increased levels 
of IgG antibodies after immunization in the absence of α4, β2, 
or α7 nAChR subunits. Of note, while the effect on antibody 
response could be directly regulated via cholinergic receptors on 
B  cells, it could also be attributed to cholinergic inhibition of 
pro-inflammatory cytokines by other immune cells, indirectly 
leading to the suppression of IgG antibodies. Also in humans, 
effects on antibody responses have been observed. When com-
paring smokers with non-smokers, the former were shown to 
exhibit lower levels of all serum immunoglobulins, except for 
IgE (82, 83). Unfortunately, cholinergic modulation of B cells in 
inflammatory conditions has been relatively unexplored until 
now, so its role in allergic inflammation remains unclear.
CHOLiNeRGiC MODULATiON OF 
ALLeRGiC eFFeCTOR CeLLS
Mast cells, basophils, and eosinophils are considered as central 
effector cells in allergic inflammation. Their activation and 
subsequent release of granule stored mediators leads to many of 
the characteristic pathophysiological features observed in allergic 
responses. Ways to modulate these effector cells and to suppress 
their activation hold promise for the development of therapeutics 
for allergic diseases. All three types of granulocytes are shown to 
express cholinergic receptors, and are thus prone to cholinergic 
modulation.
Both muscarinic and nicotinic cholinergic receptors have 
been identified on mast cells (84–86). Moreover, mast cell–nerve 
associations have been shown in both small intestine and colon 
(87–89). Vagotomy in rats resulted into a decrease of mast cells 
in the jejunal mucosa (90). VNS on the other hand was shown 
to elevate histamine levels in the jejunal wall. To what extent 
this effect was due to increased synthesis or decreased release 
of histamine remains unclear (91). Thus far, studies describ-
ing the functional effects of cholinergic mast cell modulation 
have been rather conflicting. Early studies reported activation 
rather than inhibition of mast cell degranulation by ACh via 
muscarinic receptors (92–94). Other studies, however, failed 
to show an effect of ACh on mast cell degranulation (95, 96). 
This discrepancy was addressed by Masini et  al., demonstrat-
ing that incubation with IgE increased the sensitivity of mast 
cells to ACh and induced a more homogeneous response (94). 
Nicotinic receptors on the other hand seem to mediate an anti-
inflammatory effect. Expression of nicotinic receptor subunits 
α4, α7, and β2 was found in mouse bone marrow-derived mast 
cells. In addition, nicotine was shown to inhibit antigen-IgE-
induced degranulation of mast cells in a dose dependent manner, 
an effect that was mimicked by the α7 nAChR subunit agonist, 
GTS-21. α-Bungarotoxin, a specific α7 antagonist, significantly 
inhibited the suppressive effect of GTS-21, further confirming 
the observed effect is α7 nAChR dependent (85). In line, α7, α9, 
and α10 receptor subunits are expressed in a rat mast cell/baso-
phil cell line, RBL-2H3, in which nicotine induces suppression. 
Although nicotine did not inhibit degranulation, it suppressed 
late phase FcεRI-induced leukotriene and cytokine production, 
an effect that could be abrogated by siRNA mediated ablation 
of α7, α9, or α10 nAChRs (97). Interestingly, a recent study by 
Yamamoto et al. demonstrated a potential therapeutic effect for 
the cholinergic anti-inflammatory pathway in an experimental 
murine model of food allergy. Vagal stimulation by using 
2-deoxy-d-glucose, a central vagal stimulant, ameliorated the 
development of food allergy, and was reversed by the nAChR 
antagonist, hexamethonium. Moreover, similar effects were 
obtained with nicotine and GTS-21, indicating the involvement 
of α7 nAChR. It was suggested that the amelioration of allergic 
symptoms where due to the suppression of mucosal mast cells; 
however, no direct evidence was provided. The possible involve-
ment of other immune cells can thus not be excluded (89).
Basophils share many similarities with mast cells and are often 
considered as their circulating counterparts. However, the cho-
linergic modulation of basophils has been far less investigated 
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compared with mast cells. So far, the earlier mentioned rat mast 
cell/basophil cell line, RBL-2H3 was shown to express α7, α9, 
and α10 nAChR receptor subunits (97). In addition, fluorescently 
labeled α-bungarotoxin was shown to bind to the surface of a 
human basophil cell line, and more recently the presence of 
nAChR α4, α7, and α1/α3/α5 subunits was shown in human 
blood basophils by flow cytometry (98, 99). In parallel with the 
observations in mast cells, Thompson-Cree et  al. showed that 
nicotine agonists were able to inhibit IgE-induced histamine 
release from human peripheral blood basophils (100). In addi-
tion, a recent study showed similar in vitro and in vivo inhibition 
of human blood basophils from mild allergic asthma patients 
using ASM-024, a novel compound with nicotinic and mus-
carinic effects (99). The anti-inflammatory effect of ASM-024 
was moreover confirmed in a murine model of allergic airway 
inflammation (101).
Eosinophil–cholinergic nerve interactions have been docu-
mented in several tissue compartments under inflammatory 
conditions, including lung, intestine, nose, and skin (102–108). 
The interaction between eosinophils and nerves seems to be 
mediated via adhesion molecules ICAM-1 and VCAM-1 and has 
been correlated with cholinergic nerve remodeling (103, 109). 
Eosinophil adhesion results in degranulation leading to the 
release of mediators such as major basic protein (MBP) and 
eosinophil peroxidase (EPO) (103). Binding of MBP and EPO 
leads to increased release of ACh due to upregulation of choline 
acetyltransferase and vesicular ACh transporter gene expression, 
and in addition due to antagonistic effect on inhibitory M2 recep-
tors (110–112). Recently, modulation of cholinergic nerves by 
eosinophils has become increasingly clear and might contribute 
to pathological processes, such as smooth muscle contraction 
and increased mucus production, observed in allergic condi-
tions. However, a possible anti-inflammatory effect of ACh on 
eosinophils should not be discarded. Expression of α3, α4, and α7 
nAChR subunit transcripts and protein has been demonstrated 
in human blood cells. Moreover, it was shown that stimulation 
of these cells in vitro with DMPP, a nicotinic agonist, downregu-
lated eosinophil function. DMPP inhibited LTC4 production, 
eosinophil migration, MMP-9 production, and intracellular 
calcium mobilization (113). In addition, DMPP was used earlier 
in an in vivo model of asthma, where it prevented airway hyper-
responsiveness and reduced the number of lymphocytes and 
eosinophils. The obtained results could be in part attributed to 
the observed effects on eosinophil function; however, additional 
effects on other immune cells cannot be excluded (113, 114).
CONCLUSiON
In recent years substantial advances have been made with 
respect to understanding the complex interactions between 
the nervous system and the immune system. The findings 
described in this review have highlighted a so far underap-
preciated role for the parasympathetic nervous system and 
cholinergic modulation in controlling type 2 adaptive immune 
responses. Several key players of the pathophysiological 
mechanism underlying allergic disorders are subject to cho-
linergic modulation (Figure 1) and could thus be exploited in 
the search for new therapeutic approaches to treat allergies. 
However, it should be noted that neuroimmune modulation 
is not only limited to the parasympathetic nervous system. 
Different neurotransmitters, originating from the parasym-
pathetic, sympathetic, and ENS, are able to influence each 
other. For instance, neurotransmitters of the parasympathetic 
and the sympathetic nervous system are often found to exert 
antagonistic effects. In addition, immune cells render an 
enormous plasticity what expression of neurotransmitter 
receptors is concerned. A number of factors including the local 
microenvironment, which will differ in health versus disease, 
the maturation or activation state of cells, will influence 
receptor expression. Predicting the outcome of therapeutic 
interventions using specific receptor agonists and antagonists 
will therefore be challenging. A deeper understanding of how 
the different branches of the nervous system interact with each 
other and with the immune system, in both homeostasis and 
inflammation, will hold considerable promise for the develop-
ment of new and innovative therapeutic strategies for allergic 
disorders and other inflammatory conditions.
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